Clinical relevance of invasion factors urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 for individualized therapy decisions in primary breast cancer is greatest when used in combination

Journal of Clinical Oncology

Volumn 20, Issue 4, 2002, Pages 1000-1007

  Harbeck, Nadia ^a   Kates, Ronald E ^a   Schmitt, Manfred ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; PLASMINOGEN ACTIVATOR INHIBITOR 1; UROKINASE;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER INVASION; CANCER RECURRENCE; CANCER STAGING; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MASTECTOMY; MEDICAL DECISION MAKING; MENOPAUSE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; TREATMENT PLANNING;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DECISION MAKING; DISEASE-FREE SURVIVAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PATIENT CARE PLANNING; PLASMINOGEN ACTIVATOR INHIBITOR 1; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; RISK ASSESSMENT; URINARY PLASMINOGEN ACTIVATOR;

EID: 0037083657     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.20.4.1000     Document Type: Article

References (31)

1. Clinical impact of the plasminogen activation system in tumor invasion and metastasis: Prognostic relevance and target for therapy
2. The urokinase-type plasminogen activator system in cancer metastasis: A review
3. Urokinase-plasminogen activator, a new and independent prognostic marker in breast cancer
4. Clinical relevance of the urokinase-type and tissue type plasminogen activators and of their type 1 inhibitor in breast cancer
5. High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis
6. Plasminogen activator inhibitor-1 and prognosis in primary breast cancer
7. Urokinase plasminogen activator, a strong independent prognostic factor in breast cancer, analysed in steroid receptor cytosols with a luminometric immunoassay
8. Markers of tumor angiogenesis and proteolysis independently define high- and low-risk subsets of node-negative breast cancer patients
9. Prognostic impact of urokinase-type plasminogen activator (PA), PA inhibitor type-1 and tissue-type PA antigen levels in node-negative breast cancer: A prospective study on multicenter basis
10. Prognostic significance of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in primary breast cancer
11. Low cathepsin D and low plasminogen activator type 1 inhibitor in tumor cytosols defines a group of node negative breast cancer patients with low risk of recurrence
12. Dissemination index based on plasminogen activator system components in primary breast cancer
13. Plasminogen activator inhibitor-1 (PAI-1) is not related to response to neoadjuvant chemotherapy in breast cancer
14. Urokinase (uPA) and PAI-1 as selection criteria for adjuvant chemotherapy in axillary node-negative breast cancer patients
15. Urokinase-type plasminogen activator and its inhibitor PAI-1: Predictors of poor response to tamoxifen therapy in recurrent breast cancer
16. Randomized adjuvant therapy trial in high-risk lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1
17. Invasion marker PAI-1 remains a strong prognostic factor after long-term follow-up both for primary breast cancer and following first relapse
18. Both the cytosols and detergent extracts of breast cancer tissues are suited to evaluate the prognostic impact of the urokinase-type plasminogen activator and its inhibitor, plasminogen activator inhibitor type 1
19. Risk-group discrimination in node-negative breast cancer using invasion and proliferation markers: Six-year median follow-up
20. External quality assessment of trans-European multicenter antigen determinations (enzyme-linked immunosorbent assay) of urokinase-type plasminogen activator (uPA) and its type-1 inhibitor (PAI-1) in human breast cancer tissue extracts
21. Immunohistochemical expression of uPA, uPA-R, and PAI-1 in breast carcinoma
22. uPA and PAI-1 ready for routine testing in primary breast cancer: Pooled analysis (n=8,377) provides level-1 evidence for clinical relevance
23. HER-2/neu gene amplification characterized by fluorescence in situ hybridization: Poor prognosis in node-negative breast carcinomas
24. HER-2/neu gene amplification determined by in-situ hybridization (FISH) allows risk group assessment in node-negative breast cancer
25. Time-varying prognostic impact of tumor biological factors urokinase (uPA), PAI-1, and steroid hormone receptor status in primary breast cancer
26. Survey of breast cancer patients concerning their knowledge and expectations of adjuvant therapy
27. Meeting highlights: International consensus panel on the treatment of primary breast cancer
28. Steroid receptors and other prognostic factors in primary breast cancer
29. Breast cancer prognostic factors: Evaluation guidelines
30. Tumor marker utility grading system: A framework to evaluate clinical utility of tumor markers
31. Do we need better prognostic factors in node-negative breast cancer? Arbiter